The 7 most important brand moments for biotech and life science companies

There are certain inflection points for biotech and life science companies when it's worth stepping back and asking: what are we actually communicating right now and to whom? Does the way we’re showing up match where we actually are? Leadership teams often don't think about it until something forces their hand.

Here are 7 key moments where it might make sense to reconsider the brand story:

1- Series B close (or later rounds)

Your investor narrative is solidifying. You're making your first non-founder hires. People are now carrying your story without you in the room.

2 - New CEO or CMO appointment

New leaders rarely want to inherit a narrative they had no hand in shaping. The reassessment almost always happens. The question is whether it's intentional or not.

3 - IND filing or Phase 1 initiation

You're no longer just a platform story. Clinical identity starts to matter, and partnership conversations are beginning.

4- Major BD or licensing deal

Two organizations now need to tell a coherent story together. That's harder than it looks.

5 - Platform expansion into a new modality or geography

What made you credible in your first space doesn't automatically transfer to the next one.

6 - FDA approval or commercial launch

Your audience just got a lot bigger and more varied. The story that worked in a scientific context needs to work harder across a wider range of audiences.

7 - M&A or significant partnership

Every stakeholder on both sides is forming new impressions. There's usually a short window to shape what those are.

The companies that handle these transitions well aren't necessarily doing more. They're just being intentional about it at the right moment.